Published in Cancer Res on March 01, 1989
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer (1996) 1.40
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer (1992) 0.99
New experimental models for aromatase inhibitor resistance. J Steroid Biochem Mol Biol (2007) 0.96
The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer (1990) 0.85
Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione. Br J Cancer (1993) 0.83
Hormonal effects of MPV-2213ad, a new selective aromatase inhibitor, in healthy male subjects. A phase I study. Br J Clin Pharmacol (1998) 0.83
Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer (1995) 0.83
Indirect androgen doping by oestrogen blockade in sports. Br J Pharmacol (2008) 0.83
4-hydroxyandrostenedione--further clinical and extended endocrine observations. Br J Cancer (1990) 0.81
Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer. Br J Cancer (1994) 0.79
Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective. J Med Chem (2016) 0.78
Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer. Br J Cancer (1991) 0.77
Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. Br J Cancer (1994) 0.76
Aromatase inhibitor strategies in metastatic breast cancer. Int J Womens Health (2010) 0.76
Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer. Br J Cancer (1992) 0.75
Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med (1996) 5.69
Effect of open peer review on quality of reviews and on reviewers' recommendations: a randomised trial. BMJ (1999) 5.45
What makes a good reviewer and a good review for a general medical journal? JAMA (1998) 5.01
Effect of blinding and unmasking on the quality of peer review: a randomized trial. JAMA (1998) 4.03
Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry (1999) 3.95
The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat Med (1999) 3.53
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
High early mortality rate from acute pancreatitis in Scotland, 1984-1995. Br J Surg (1999) 2.78
Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg (2002) 2.72
Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. Control Clin Trials (2000) 2.67
The use of antisera to epithelial membrane antigen in detecting micrometastases in histological sections. Br J Cancer (1980) 2.50
Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology (2010) 2.40
Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet (1974) 2.30
Malignant melanoma and exposure to fluorescent lighting at work. Lancet (1982) 2.28
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res (2001) 2.15
Death rates of characters in soap operas on British television: is a government health warning required? BMJ (1998) 2.12
Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer (1992) 2.10
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Ablation of Cypher, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. J Cell Biol (2001) 2.09
Detection of micrometastases in patients with primary breast cancer. Lancet (1983) 2.07
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med (1996) 1.97
Candidate genes for the hypoxic tumor phenotype. Cancer Res (2000) 1.94
Conservative management of erosion-abrasion: a system for the general practitioner. Aust Dent J (1994) 1.90
Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet (1980) 1.88
Restriction fragment length polymorphism of polymerase chain reaction products applied to the differentiation of poultry campylobacters for epidemiological investigations. Res Vet Sci (1996) 1.86
Cutaneous factors related to the risk of malignant melanoma. Br J Dermatol (1983) 1.85
Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res (1994) 1.84
CARP, a cardiac ankyrin repeat protein, is downstream in the Nkx2-5 homeobox gene pathway. Development (1997) 1.83
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
Surgical options for the treatment of severe tibial pilon fractures: a study of three techniques. J Orthop Trauma (2001) 1.82
Survey of treatment of primary breast cancer in Great Britain. Br Med J (Clin Res Ed) (1985) 1.80
Defining radiographic osteoarthritis for the whole knee. Osteoarthritis Cartilage (1997) 1.80
Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia (2000) 1.79
Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell (2000) 1.77
Sedation for oocyte retrieval using target controlled infusion of propofol and incremental alfentanil delivered by non-anaesthetists. Anaesthesia (2010) 1.74
X-ray refraction effects: application to the imaging of biological tissues. Br J Radiol (2003) 1.73
Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer (1983) 1.73
Diagnosing breast carcinoma in young women. BMJ (1991) 1.71
Are elevated liver enzymes and bilirubin levels significant after laparoscopic cholecystectomy in the absence of bile duct injury? Ann Surg (1994) 1.69
FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer (2000) 1.68
Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J (1997) 1.60
Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol (1999) 1.60
Psychiatric disorder among children at time of entering local authority care: questionnaire survey. BMJ (1999) 1.57
Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A (2001) 1.55
Topical calcipotriol treatment in advanced breast cancer. Lancet (1991) 1.53
Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol (1997) 1.51
Estrogen and progesterone receptors in the normal female breast. Cancer Res (1991) 1.50
Failure of dietetic referral in patients with gastrointestinal cancer and weight loss. Eur J Cancer (2006) 1.50
Biochemical markers in human breast cancer. Lancet (1977) 1.48
Factors influencing the distribution of tuberculosis cases in an inner London borough. Commun Dis Public Health (2000) 1.47
Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg (2000) 1.46
BMP signaling is required for heart formation in vertebrates. Dev Biol (2000) 1.46
Perforating granuloma annulare complicating tattoos. Br J Dermatol (1998) 1.45
Inhibition of human red blood cell glutathione reductase by valproic acid. Biochem Pharmacol (1992) 1.44
Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem (1997) 1.42
Physical test for distant metastases in patients with breast cancer. J R Soc Med (1980) 1.42
Muscle acetylcholine receptor biosynthesis. Regulation by transcript availability. J Biol Chem (1987) 1.41
Estrogen receptor beta in breast cancer. Endocr Relat Cancer (2002) 1.41
Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer (1981) 1.39
Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol (1986) 1.39
Seminal vesicle cysts and associated anomalies. BJU Int (2002) 1.38
Gastroesophageal reflux in children. Clinical profile, course and outcome with active therapy in 126 cases. Clin Pediatr (Phila) (1987) 1.38
Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol Psychiatry (2006) 1.38
Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clin Infect Dis (1994) 1.38
Ingested arsenic, keratoses, and bladder cancer. Am J Epidemiol (1992) 1.37
Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J (Clin Res Ed) (1987) 1.36
Epidermal growth factor receptors in lung tumours. J Pathol (1987) 1.36
Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet (1989) 1.36
Predictors of ovarian reserve in young women with breast cancer. Br J Cancer (2007) 1.35
Societal responsibilities of clinical trial sponsors. Lack of commercial pay off is not a legitimate reason for stopping a trial. BMJ (2001) 1.35
4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet (1984) 1.35
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer (2008) 1.34
FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene (2010) 1.34
Cloning, sequencing, and expression of a xylanase gene from the anaerobic ruminal bacterium Butyrivibrio fibrisolvens. J Bacteriol (1990) 1.34
Isolation of pure populations of epithelial and myoepithelial cells from the normal human mammary gland using immunomagnetic separation with Dynabeads. Anal Biochem (1995) 1.33
Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol (2000) 1.33
Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci U S A (1999) 1.32
Occupational asthma caused by nickel sulfate. J Allergy Clin Immunol (1982) 1.29
Disc degeneration/back pain and calcification of the abdominal aorta. A 25-year follow-up study in Framingham. Spine (Phila Pa 1976) (1997) 1.28
Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet (1999) 1.28
Requirement of a novel gene, Xin, in cardiac morphogenesis. Development (1999) 1.28
Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients. Br J Cancer (2012) 1.27
Eating in preschool children with cystic fibrosis and healthy peers: behavioral analysis. Pediatrics (1995) 1.26
The human mammary gland basement membrane is integral to the polarity of luminal epithelial cells. Exp Cell Res (1999) 1.26
Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer (2009) 1.25
Growth factor expression in normal, benign, and malignant breast tissue. Br Med J (Clin Res Ed) (1988) 1.24
Molecular mechanisms involved in morphological variation of avian sarcoma virus-infected rat cells. Virology (1982) 1.24
Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer (1991) 1.23
Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab (1988) 1.22
Azathioprine and penicillamine in treatment of rheumatoid arthritis: a controlled trial. Br Med J (1976) 1.22
Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J Biol Chem (1995) 1.22
Effect of blinding and unmasking on the quality of peer review. J Gen Intern Med (1999) 1.21
Transplant renal artery stenosis in 77 patients--does it have an immunological cause? Transplantation (1996) 1.21
Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer (2006) 1.20
Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol (1994) 1.19